A recent study has found that patients with HIV are six times more likely to have schizophrenia compared with those who do not have the virus.
Kevin Kunzmann
Advertisement
Kevin Kunzmann is the managing editor for Contagion, as well as its sister publication HCPLive. Prior to joining parent company MJH Life Sciences in 2017, he worked as a health care and government reporter for The Pocono Record, and as a freelance writer for NJ Advance Media, The Express-Times, The Daily Journal, and more. He graduated from Rowan University with a degree in journalism in 2015. In his spare time, he enjoys reading, cooking, running his dog, and complaining about the Mets. Follow him on Twitter @NotADoctorKevin or email him at kkunzmann@mjhlifesciences.com
Articles by Kevin Kunzmann
The CDC’s Advisory Committee on Immunization Practices has included HEPLISAV-B on its list of recommended products for use to vaccinate adults against hepatitis B.
An international research team finds that targeting the social and risk networks of patients recently diagnosed with HIV is leading them to more patients unknowingly infected with the virus.
An accredited dentist suggests that practiced care for the mouth and teeth could potentially help individuals during flu season.
A FDA committee decided against recommending approval for Linhaliq to treat NCFBE patients with chronic lung Pseudomonas aeruginosa infections.
The FDA has approved Merck’s ISENTRESS to be used in combination with other antiretroviral agents to treat HIV-1 in certain newborns.
The FDA approves the first test designed to detect Zika virus in blood donations.
A FDA expert advisory panel voted unanimously to back a new shingles vaccine developed by GlaxoSmithKline: Shingrix.
Janssen announces a strategic decision to discontinue the development of investigational hepatitis C treatment, JNJ-4178, a triple-combination drug, consisting of three direct-acting antivirals.
Kedrion Biopharma and Kamada Ltd. recently announced that KEDRAB, a post-exposure prophylaxis to be used against rabies infection has just been approved by the FDA.
The decision date for a NDA for a new hepatitis B vaccine, Dynavax’s Heplisav-B, has been delayed, as the FDA asked for more post-marketing study information on the vaccine.
The US Food and Drug Administration approved Mavyret for adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis or with mild cirrhosis.
In a 12-1 vote, the FDA’s Vaccines and Related Biological Products Advisory Committee supported the safety data of a new potential hepatitis B vaccine.
Nader Pourhassan, PHD, president and chief executive officer of CytoDyn, the biotechnology company that acquired PRO 140, offers insight into the antibody as treatment for HIV.
Research published in Molecular Therapy in early May could help uncover latent HIV-1 cells that serve as a viral reservoir.
Advertisement
